CharlesAKunosMDPhD

Radiation Oncology • Miami, FL

Assistant Professor of Radiation Oncology, Case West Res University

Join to view full profile

Dr. Kunos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kunos' full profile

Already have an account?

Office
1475 NW 12th Ave
Miami, FL 33136
Phone+1 305-243-8643

Fax+1 330-376-1302

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Radiation Oncology, 2002 - 2006
The MetroHealth System/Case Western Reserve UniversityInternship, Internal Medicine, 2001 - 2002
Case Western Reserve University School of MedicineClass of 2001

Certifications & Licensure

OH State Medical License 2001 - 2026
FL State Medical License 2023 - 2025
KY State Medical License 2020 - 2024
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer Start of enrollment: 2005 Apr 01
Withdrawn
Phase 1
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies Start of enrollment: 2006 Mar 01
Completed
Phase 1
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 2
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Start of enrollment: 2012 Dec 06
Completed
Phase 2
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2012 Dec 20
Completed
Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer Start of enrollment: 2013 Mar 22
RECRUITING
PHASE2, PHASE3
Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine® NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and S Start of enrollment: 2013 Apr 01
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Start of enrollment: 2013 Aug 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892).
Sarah E Taylor, Sarah Behr, Kristine L Cooper, Haider Mahdi, Denise Fabian
Cancer Chemotherapy and Pharmacology. 2024-12-14
Cisplatin-Containing Combinations Associate with Survival in Women from Appalachian Kentucky with Metastatic, Persistent, or Recurrent Uterine Cervix Cancer.
Charles A Kunos, Rachel W Miller, Denise Fabian
Cancers. 2024-09-28
Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic.
Charles A Kunos, Molly E Martin, Michalis F Georgiou, Russ A Kuker, Aman Chauhan
Cancers. 2024-04-02

Abstracts/Posters

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
Charles Kunos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Coming Soon? New Treatments in Ovarian Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018

Press Mentions

Markey Cancer Center Study Shows Potential for New Radiopharmaceutical Cancer TreatmentFebruary 24th, 2023
Radiation Drugs Hunt and Kill Cancer CellsJune 8th, 2021
Radiopharmaceuticals: Radiation Therapy Enters the Molecular AgeOctober 26th, 2020